AlphAIalphai — Financial news for AI agents
tipranks.comJUL 302 min read$VKTX

Viking Therapeutics price target raised to $114 from $107 at Canaccord - TipRanks.com

Canaccord raised the firmâs price target on Viking Therapeutics (VKTX) to $114 from $107 and keeps a Buy rating on the shares. The firm said the company beat on the bottom line, reporting a loss of $1.10 per share compared to estimates of a $1.35 per share loss and the consensus estimate of a $1.23 per share loss. Management guided for lower cash expenditure in 2027 but is actively expanding their workforce.

Original reporting
tipranks.com
Published Jul 30, 2026, 12:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 6:28 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$VKTX
Bullish
medium confidence
Mentioned
$VKTX
Relevance
4/10
alphai data visualization · based on tipranks.com
Decision brief

The 30-second read

$VKTXBullishLow
01

Why it matters

The trading takeaway is the PT raise to $114 from $107 with a maintained Buy, justified by an earnings beat and guidance for lower 2027 cash expenditure while expanding headcount.

02

Market read

For VKTX traders, the incremental signal is sell-side sentiment improvement, not a new fundamental event like trial readouts or regulatory action.

03

What to watch

The article highlights lower cash expenditure guidance for 2027 but does not quantify it, and it notes workforce expansion, which could offset cash savings if burn accelerates later.

Relevance 4/10Novelty 4/10Timing: today’s analyst price-target update

Background

The piece is a TipRanks/TheFly repost summarizing Canaccord’s post-results analyst action on Viking Therapeutics.

Company-level read

Ticker impact

$VKTXBullishMedium confidence
Context

Canaccord raised Viking Therapeutics price target to $114 from $107 and kept a Buy after the company beat bottom-line estimates and guided lower 2027 cash spend.

Expected impact

Likely supports upside bias versus prior PT, but magnitude depends on whether the market already priced the earnings beat and 2027 cash-expenditure guidance.

Evidence & confidence

The only new actionable items here are the PT change and the cited beat plus 2027 cash-expenditure direction; no new clinical, regulatory, or financing event is disclosed in the text.

Market effects

Sector

Reinforces bullish sell-side framing for obesity/biopharma names tied to cash discipline and execution.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A higher PT from one firm may not change fundamentals if the market already expects cash burn improvement and the earnings beat is not accompanied by new clinical catalysts.

Key entities

  • company
    Viking Therapeutics

    Obesity-focused biopharma whose price target was raised after an earnings beat and cash-expenditure guidance for 2027.

  • analyst_firm
    Canaccord

    Raised the firm’s price target and kept a Buy rating.

Read at source← All news

Related articles

AUG 4
$VKTXMedAI 8/10

Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?

Viking Therapeutics (VKTX) reported a wider Q2 2026 net loss of $128.02 million and filed a universal shelf registration plus a $500 million at-the-market common stock offering, expanding funding options. The article links these moves to investor expectations for VK2735 obesity drug development, noting dilution and cash burn risks and citing forecasts of $118.5 million revenue and $12.9 million earnings by 2029.

simplywall.st5 min
JUL 29
$VKTXMed

Viking Therapeutics, Inc. (VKTX): Results of Operations and Financial Condition

Viking Therapeutics, Inc. (VKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enroll

SEC EDGAR 8-K6 min
MAY 27
$VKTXMedAI 8/10

Truist Financial Begins Coverage on Viking Therapeutics (NASDAQ:VKTX)

Truist Financial began coverage of Viking Therapeutics (VKTX) with a “buy” rating and an $83.00 price target, implying 159.5% upside from the prior close, according to the firm. Other analysts set targets from $95 to $102 and ratings ranging from “buy” to “sell.” VKTX shares traded at $31.99 midweek; it reported Q1 EPS of ($1.37), missing the ($1.01) consensus.

tickerreport.com4 min
MAY 26
$VKTXHighAI 9/10

If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders and analysts are focusing on Viking Therapeutics (VKTX) as an obesity M&A target, citing an estimated 38.5% implied acquisition probability before 2027. The company has no revenue and a ~$3.59B market cap; shares closed at $30.89 on May 22, 2026. Analysts’ mean target is $92.33. Viking’s oral VK2735 showed up to 12.2% weight loss at 13 weeks, and Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Potential buyers mentioned include Eli Lilly, Pfizer, and Novo Nordisk.

finance.yahoo.com7 min
MAY 26
$VKTXMedAI 8/10

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The article argues that obesity-drug demand could drive growth in 2026 and highlights two stocks. Viking Therapeutics (VKTX) is advancing VK-2735, a dual GLP-1/GIP agonist, in phase 3; it expects oral phase 3 later this year and phase 3 data in Q3. AbbVie (ABBV) reported 12% revenue growth to $15B in the latest quarter and is developing ABBV-295, an amylin analog, with phase 1 weight loss of >7% to >9% in 12–13 weeks.

fool.com7 min